Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Join Medicilon at Precision in Drug Discovery & Preclinical Summit

2022-01-07
|
Page View:

Join Medicilon at Precision in Drug Discovery & Preclinical Summit.png

We are excited to announce that Medicilon will exhibit at Precision in Drug Discovery & Preclinical (PDDP) Summit. The European PDDP summit series is coming to Frankfurt, Germany in September 27th-28th, 2022. Please come and join the Medicilon team at Booth 3. We are happy to meet you in person to discuss how our services and capabilities can support your research and expedite your drug discovery and development activities. 


ABOUT Precision in Drug Discovery & Preclinical 2022 Summit

The Precision in Drug Discovery & Preclinical event will be a unique platform for the largest bio-pharmaceutical hub in the region to network and discuss collaboration in order to achieve their discovery and scientific strategies. This gathering will showcase the progress and latest research trends that include new compounds, drug design, synthesis methods and technologies that advance the science from leaders in the pharma-biotech and academic spaces. With an innovation-focused agenda, pre-scheduled meetings between potential collaborators and a host of reliable service providers, the summit is designed to help attendees find solutions to their most pressing research challenges in 2021 and beyond.


ABOUT Medicilon

From its inception in 2004, Shanghai Medicilon Inc. (STAR Market stock code: 688202.SH) has been committed to providing comprehensive research and development (R&D) services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space, with the primary objective of supporting and accelerating pharmaceutical, biopharmaceutical R&D worldwide.

At Medicilon, we are dedicated to help our clients develop their research and discovery programs from initial idea all the way through the Investigational New Drug (IND) filing phase. Our services span across medicinal chemistry, biology, API, CMC, formulation, and preclinical studies. We provide flexible business models, including stand-alone Fee for Services (FFS) and fully integrated FTE services. In addition, our facilities are GLP/GMP compliant, US-FDA, China NMPA and AAALAC accredited. All study reports can be presented in SEND format, supporting dual filing of IND applications in the US, EU, and China.

Medicilon-Preclinical-CRO.png


Innovative Drug R&D Services

Antibody-Drug Conjugate (ADC)

Medicilon offers clients with a pool of payload drugs of various mechanisms and offers custom synthesis of payload drugs. Medicilon fully understands the complexity of ADA evaluation and offers our clients with comprehensive immunogenicity assays.

Proteolysis Targeting Chimera (PROTAC) 

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules. Medicilon has established a complete PROTAC in vitro analysis platform.

mRNA Vaccine Bioanalysis Platform

Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines.  We have accumulated rich experience on this technology; therefore, we establish the bioanalysis platform for mRNA vaccines. Based on the mechanism and characteristics of mRNA vaccines, Medicilon’s Bioanalysis Department has established an evaluation platform covering metabolism and biodistribution, key sequence domain antibodies and antiviral neutralizing antibody titers and the evaluation of effectiveness of cellular immune response.

AI R&D Innovation

As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning.  Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model.  Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.

Cellular Immunotherapies

Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers.  With the continuous discovery of tumor targets and mechanisms, the track is still full of vitality and hope bringing new breakthroughs in tumor treatment and human welfare. Medicilon has built a one-stop research platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

Our EU BD Vice President, Dr. Paul van Stralen, will be hosting the booth in the conference. Please feel free to visit him for detailed information on Medicilon’s integrated services. Join us at PDDP Europe for a two-day journey into the insightful world of drug discovery and preclinical drug development.
Relevant newsRelevant news